Top Markets
Coin of the day
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
Peringkat dalam Saham #32696
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Harga Saham
$0.10046734
Kapitalisasi Pasar
$9.46M
Perubahan (1 hari)
32.34%
Perubahan (1 tahun)
-21.98%
Negara
DE
Perdagangan TME Pharma N.V. (ALTME)

Kategori

Jumlah saham beredar untuk TME Pharma N.V. (ALTME)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham TME Pharma N.V., jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk TME Pharma N.V. (ALTME) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE